Targeting VEGF has emerged as a key component in the treatment of CNV linked to AMD, as evidenced by the discovery that decreased expression levels of MMP-9 and VEGF relieve CNV generation in animal models by lowering the HIF-1α/VEGF/VEGFR2 pathway [28]. Here, VEGFA is linked to age-related macular degeneration.